Allergy Therapeutics successful primary outcome of VLP Peanut 001
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, has announced positive primary results from an ex-vivo biomarker study evaluating the Group’s novel virus-like particle (VLP)